Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2198-6584
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study ; volume:6 ; number:4 ; day:13 ; month:8 ; year:2019 ; pages:503-520 ; date:12.2019
Rheumatology and therapy ; 6, Heft 4 (13.8.2019), 503-520, 12.2019
- Urheber
-
Genovese, Mark C.
Greenwald, Maria W.
Gutierrez-Ureña, Sergio R.
Cardiel, Mario H.
Poiley, Jeffrey E.
Zubrzycka-Sienkiewicz, Anna
Codding, Christine E.
Wang, Annie
He, Weizhong
Amos, Rebecca
Vinueza, Raul
Wang, Xuegong
Garg, Jay P.
Kivitz, Alan J.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40744-019-00167-6
- URN
-
urn:nbn:de:101:1-2020031405474774306576
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:45 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Genovese, Mark C.
- Greenwald, Maria W.
- Gutierrez-Ureña, Sergio R.
- Cardiel, Mario H.
- Poiley, Jeffrey E.
- Zubrzycka-Sienkiewicz, Anna
- Codding, Christine E.
- Wang, Annie
- He, Weizhong
- Amos, Rebecca
- Vinueza, Raul
- Wang, Xuegong
- Garg, Jay P.
- Kivitz, Alan J.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Celiac Disease in Children with Moderate-to-Severe Iron-deficiency Anemia
Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy
MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Induced hypernatremia in patients with moderate-to-severe ARDS: a randomized controlled study
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Celiac Disease in Children with Moderate-to-Severe Iron-deficiency Anemia
Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy
MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Induced hypernatremia in patients with moderate-to-severe ARDS: a randomized controlled study
Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
Celiac Disease in Children with Moderate-to-Severe Iron-deficiency Anemia
Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study
Teprotumumab: The Dawn of Therapies in Moderate-to-Severe Thyroid-Associated Ophthalmopathy
MP-AzeFlu in Moderate-to-Severe Allergic Rhinitis: A Literature Review
Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Long-Term Safety and Efficacy of Risankizumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: Results from a Phase 2 Open-Label Extension Trial
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis